P. Hogan

发表

Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies

M. Bassetti, D. Kontoyiannis, M. Capparella, 2017, Mycoses.

Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013

Ronald N. Jones, R. Mendes, R. Flamm, 2015, Antimicrobial Agents and Chemotherapy.

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.

D. Low, J. Karlowsky, G. Zhanel, 2014, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.

J. Karlowsky, M. Jones, D. Sahm, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)

Ronald N. Jones, R. Mendes, R. Flamm, 2016, Antimicrobial Agents and Chemotherapy.

Macrolide Susceptibility and β-Lactamase Production among Haemophilus influenzae Isolates in the United States, 1996–1997

D. Sheehan, P. Hogan, 1998, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity and Resistance Development Profiling of Dalbavancin

B. Goldstein, D. Sahm, D. Sheehan, 2007, Antimicrobial Agents and Chemotherapy.

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

D. Sahm, D. Sheehan, P. Hogan, 2006, Annals of Clinical Microbiology and Antimicrobials.

Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program

Ronald N. Jones, T. Fritsche, H. Sader, 2006, Journal of Clinical Microbiology.

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries

M. Pfaller, R. Mendes, R. Flamm, 2017, The Journal of antimicrobial chemotherapy.

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).

Ronald N. Jones, R. Mendes, R. Flamm, 2014, The Journal of antimicrobial chemotherapy.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Ronald N. Jones, D. Farrell, R. Mendes, 2015, Diagnostic microbiology and infectious disease.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries

M. Castanheira, H. Sader, R. Mendes, 2018, The Journal of antimicrobial chemotherapy.

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)

M. Pfaller, R. Mendes, R. Flamm, 2017, Antimicrobial Agents and Chemotherapy.

Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting.

D. Sahm, Deborah C. Draghi, P. Hogan, 2006, Diagnostic microbiology and infectious disease.

Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

Stephen F Eckel, William Krebs, M. Zervos, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, D. Sheehan, P. Hogan, 2007, Antimicrobial Agents and Chemotherapy.

Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015

H. Sader, R. Mendes, R. Flamm, 2016 .

Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms

Ronald N. Jones, R. Mendes, R. Flamm, 2015 .

In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program

D. Sahm, D. Sheehan, Deborah C. Draghi, 2005, Antimicrobial Agents and Chemotherapy.

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.

Ronald N. Jones, H. Sader, R. Mendes, 2016, The Journal of antimicrobial chemotherapy.

Methicillin-Resistant Staphylococcus aureus SCC mec Type and Its Association with Clinical Presentation, Severity, and Length of Stay among Patients with Complicated Skin and Skin Structure Infections

David B. Huang, P. Hogan, D. Myers, 2014 .

Clinical Outcomes by Methicillin-Resistant Staphylococcus aureus Staphylococcal Cassette Chromosome mec Type: Isolates Recovered from a Phase IV Clinical Trial of Linezolid and Vancomycin for Complicated Skin and Skin Structure Infections

A. Reisman, David B. Huang, P. Hogan, 2010, Antimicrobial Agents and Chemotherapy.

Annals of Clinical Microbiology and Antimicrobials Laboratory-based Surveillance of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 2005 Status in the United States

D. Sahm, D. Sheehan, P. Hogan, 2022 .

Differences in Antimicrobial Susceptibility Among Hospitals in an Integrated Health System

T. Lubowski, P. Hogan, J. Woon, 2001, Infection Control & Hospital Epidemiology.

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.